Synthesis of novel 1,3,4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents

Chemical and Pharmaceutical Bulletin

Volumn 51, Issue 7, 2003, Pages 838-844

  Abadi, Ashraf Hassan ^a   Eissa, Amal Abdel Haleem ^a   Hassan, Ghaneya Sayed ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

1,3,4 trisubstituted pyrazoles; Antiangiogenic; Anticancer; Endothelial cell

Indexed keywords

3 ACETYL 2 [1 (4 NITROPHENYL) 3 PHENYLPYRAZOL 4 YL] 5 (3 PYRIDYL) 1,3,4 OXADIAZOLINE; 3 ACETYL 2 [1 (4 NITROPHENYL) 3 PHENYLPYRAZOL 4 YL] 5 (4 PYRIDYL) 1,3,4 OXADIAZOLINE; 3 ACETYL 2 [3 (4 BROMOPHENYL) 1 (4 NITROPHENYL)PYRAZOL 4 YL] 5 (3 PYRIDYL) 1,3,4 OXADIAZOLINE; 3 ACETYL 2 [3 (4 BROMOPHENYL) 1 (4 NITROPHENYL)PYRAZOL 4 YL] 5 (4 PYRIDYL) 1,3,4 OXADIAZOLINE; 3 ACETYL 5 [2 CHLORO(3 PYRIDYL)] 2 [1 (4 NITROPHENYL) 3 PHENYLPYRAZOL 4 YL] 1,3,4 OXADIAZOLINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CELECOXIB; CHEMOATTRACTANT; FUMAGILLOL CHLOROACETYLCARBAMATE; N [4 ACETYL 5 [1 (4 NITROPHENYL) 3 PHENYL 1H PYRAZOL 4 YL] 4,5 DIHYDRO[1,3,4]THIADIAZOL 2 YL] N METHYLACETAMIDE; N [4 ACETYL 5 [1 (4 NITROPHENYL) 3 PHENYL 1H PYRAZOL 4 YL] 4,5 DIHYDRO[1,3,4]THIADIAZOL 2 YL]ACETAMIDE; N' [1 [1 (4 NITROPHENYL) 3 PHENYL 1H PYRAZOL 4 YL]METHYLENE] 2 CHLOROBENZOHYDRAZIDE; N' [1 [3 (4 BROMOPHENYL) 1 (4 NITROPHENYL) 1H PYRAZOL 4 YL]METHYLENE] 2 CHLOROBENZOHYDRAZIDE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVITY; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOTOXICITY; DILUTION; DOSE RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LC 50; LETHALITY; TUMOR CELL LINE; UMBILICAL VEIN; DRUG EFFECT; METHODOLOGY; PHYSIOLOGY; SYNTHESIS; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIUM, VASCULAR; HUMANS; PYRAZOLES;

EID: 1542471130     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.51.838     Document Type: Article

References (33)

1. Joseph B., Darro F., Behard A., Lesur B., Collignon F., Decaestecker C., Frydman A., Guillaumet G., Kiss R., J. Med. Chem., 45, 2543-2555 (2002).
2. Hande K. R., Biochim. Biophys. Acta, 1400, 173-184 (1998).
3. Rust W. L., Huff J. L., Plopper G. E., Anal. Biochem., 280, 11-19 (2000).
4. Flokman J., J. Natl. Cancer Inst., 82, 4-6 (1990).
5. Yoshida A., Anand-Apte B., Zetter B. R., Growth Factors, 13, 57-64 (1996).
6. Lang Z., Guerrera M., Li R., Ladisch S., Biochem. Biophys. Res. Commun., 282, 1031-1037 (2001).
7. Folkman J., Scientific American, 275, 150-153 (1996).
8. Kerbel R. S., J. Clin. Oncol., 19, 45S-51S (2001).
9. Kudelka A. P., Verschraegen C. F., Loyer E. N., N. Engl. J. Med., 338, 991-992 (1998).
10. Taraboletti G., Margioso B., Curr. Opin. Pharmacol., 1, 378-384 (2001).
11. Hayot C., Farinelle S., De Decker R., Decaestecker C., Darro F., Kiss R., Van damme M., Int. J. Oncol., 21, 417-425 (2002).
12. Leahy K. M., Koki A. T., Masferrer J. L., Curr. Med. Chem., 7, 1163-1170 (2000).
13. Lala P. K., Al-Mutter N., Orucevic A., Int. J. Cancer, 73, 371-380 (1997).
14. Bouch N., Stellmach V., Hsu S. C., Adv. Cancer Res., 69, 135-174 (1996).
15. Connolly E. M., Harmey J. H., O'Grady T., Foley D., Roche-Nagle G., Kay E., Bouchier-Hayes D. J., Br. J. Cancer, 87, 231-237 (2002).
16. Blanke C. D., Oncology, 16, 17-21 (2002).
17. Kira M. A., Abdel-Rahman M. O., Gadalla K. Z., Tetrahedron Lett., 1969, 109-111 (1969).
18. Bernard M., Hulley E., Molenda H., Stochla K., Wrzeciono U., Pharmazie, 41, 560-562 (1986).
19. Farghaly A. A., Bekhit, A. A., Park J. Y., Arch. Pharm. Pharm. Med. Chem., 333, 53-57 (2000).
20. Greever M. R., Schepartz S. A., Chabner B. A., Semin. Oncol., 19, 622-638 (1992).
21. Boyd M. R., Paull K. D., Drug Dev. Res., 34, 91-109 (1995).
22. Monks A., Scudiero D., Dkehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langely J., Cronise P., Vaigro-Wolf M., Gray-Good Rich M., Campell H., Mayo M. R., J. Natl. Cancer Inst., 83, 757-766 (1991).
23. Bai R., Paull K. D., Herald C. L., Pettit G. R., Hamel E., J. Biol. Chem., 266, 15882-15889 (1991).
24. Paull K. D., Lin C. M., Malspeis L., Hamel E., Cancer Res., 52, 3892-3900 (1992).
25. Dennler E. B., Farasco A. R., Tetrahedron, 22, 3131-3135 (1966).
26. Gautier J. A., Compt. Rend., 222, 394-396 (1946)
27. [Chem. Abstr., 40, 3118 (1946)].
28. Miyatake K., Ichimure S., Nagasaki S., Hoji K., J. Pharm. Soc. Jpn., 75, 1066-1069 (1955)
29. [Chem. Abstr., 50, 5616 (1956)].
30. Rong Z., Xuhong Q., Yingyony Huaxue, 13, 5-8 (1996)
31. [Chem. Abstr., 126, 47158t (1997)].
32. Tarabolleti G., Micheletti G., Rieppi M., Poli M., Turatto M., Rossi C., Borsotti P., Roccabianca P., Scanziani E., Nicoletti M. I., Bombardelli E., Morazzoni P., Riva A., Giavazzi R., Clin. Cancer Res., 8, 1182-1188 (2002).
33. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M. R., Viale G., Giavazzi R., Taraboletti G., Clin. Cancer Res., 2, 1843-1849 (1991).